Meitheal Pharmaceuticals expands heparin manufacturing capacity in China

Meitheal Pharmaceuticals announced FDA approval of a new vial manufacturing line at NKF's Nanjing facility, doubling vial capacity to 100 million units. Plans include additional lines and a second Nanjing facility under construction, plus a new vial line in Chengdu.

“The new line and future expansion plans (10 total manufacturing lines) supports Meitheal's majority shareholder, NKF's commitment to ensuring capacity to supply the US market for years to come.”pharmaceuticaldaily.com

• 1 source
• pharmaceuticaldaily.comMeitheal Pharmaceuticals Announces FDA Approval of Additional Manufacturing Capacity and Future Facility Expansion Plans for Production of Heparin Sodium Injection, USP – pharmaceutical dailyBusinessWireFeb 11, 2020

Summarized from public sources; check the original articles before acting on it.